Despite the overall strong performance, the company's legacy products, Trokendi XR and Oxtellar XR, saw a decline in net sales. The company's Q3 net product sales also rose significantly to $170.3 ...

and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. Receive News & Ratings for Supernus ...

Full year 2024 revenues increased 9% to $661.8 million, compared to the same period in 2023; Full year 2024 total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP ...

However, the company's legacy products, Trokendi XR and Oxtellar XR, saw a decline in net sales. The firm's Qelbree prescriptions experienced a 19% growth, while GOCOVRI net sales saw an 8% ...

Our performance in 2024 underscored our emphasis on growing our core business despite the loss of exclusivity on both Trokendi XR and Oxtellar XR. Total revenues, excluding Trokendi XR and ...

The company has built a strong presence in the CNS market with well-known products like Qelbree for ADHD, Trokendi XR, and Oxtellar XR for epilepsy, and treatments for Parkinson’s disease such ...

It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Full year 2024 revenues increased 9% to $661.8 million, compared to the same period in 2023; Full year 2024 total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP ...